BioCentury
ARTICLE | Clinical News

ATB-346: Phase II start

March 14, 2016 7:00 AM UTC

This month, Antibe will begin an open-label, Canadian Phase II trial to evaluate once-daily 250 mg oral ATB-346 in about 12-16 patients. ...